• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

染色质重塑因子 Arid1a 通过表观遗传地上调 Siglec15 的表达与 Jun/Fos 协同促进破骨细胞生成。

The chromatin remodeling factor Arid1a cooperates with Jun/Fos to promote osteoclastogenesis by epigenetically upregulating Siglec15 expression.

机构信息

Department of Orthopedics, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, PR China.

Orthopedics Research Institute of Zhejiang University, Hangzhou, Zhejiang 310009, PR China.

出版信息

J Bone Miner Res. 2024 Jul 23;39(6):775-790. doi: 10.1093/jbmr/zjae042.

DOI:10.1093/jbmr/zjae042
PMID:38477755
Abstract

Osteoporosis is characterized by an imbalance between osteoclast-mediated bone resorption and osteoblast-related bone formation, particularly increased osteoclastogenesis. However, the mechanisms by which epigenetic factors regulate osteoclast precursor differentiation during osteoclastogenesis remain poorly understood. Here, we show that the specific knockout of the chromatin remodeling factor Arid1a in bone marrow-derived macrophages (BMDMs) results in increased bone mass. The loss of Arid1a in BMDM inhibits cell-cell fusion and maturation of osteoclast precursors, thereby suppressing osteoclast differentiation. Mechanistically, Arid1a increases the chromatin access in the gene promoter region of sialic acid-binding Ig-like lectin 15 (Siglec15) by transcription factor Jun/Fos, which results in the upregulation of Siglec15 and promotion of osteoclast differentiation. However, the loss of Arid1a reprograms the chromatin structure to restrict Siglec15 expression in osteoclast precursors, thereby inhibiting BMDM differentiation into mature osteoclasts. Deleting Arid1a after ovariectomy (a model for postmenopausal bone loss) alleviated bone loss and maintained bone mass. In summary, epigenetic reprogramming mediated by Arid1a loss suppresses osteoclast differentiation and may serve as a promising therapeutic strategy for treating bone loss diseases.

摘要

骨质疏松症的特征是破骨细胞介导的骨吸收和成骨细胞相关的骨形成之间的失衡,特别是破骨细胞生成增加。然而,表观遗传因素如何调节破骨细胞前体在破骨细胞生成过程中的分化机制仍知之甚少。在这里,我们表明,染色质重塑因子 Arid1a 在骨髓来源的巨噬细胞(BMDM)中的特异性敲除导致骨量增加。BMDM 中 Arid1a 的缺失抑制破骨细胞前体的细胞-细胞融合和成熟,从而抑制破骨细胞分化。在机制上,Arid1a 通过转录因子 Jun/Fos 增加唾液酸结合免疫球蛋白样凝集素 15(Siglec15)基因启动子区域的染色质可及性,从而上调 Siglec15 并促进破骨细胞分化。然而,Arid1a 的缺失重新编程染色质结构,从而抑制破骨细胞前体中 Siglec15 的表达,从而抑制 BMDM 分化为成熟的破骨细胞。在卵巢切除术后(绝经后骨质疏松症模型)删除 Arid1a 可减轻骨丢失并维持骨量。总之,由 Arid1a 缺失介导的表观遗传重编程抑制破骨细胞分化,可能成为治疗骨丢失疾病的有前途的治疗策略。

相似文献

1
The chromatin remodeling factor Arid1a cooperates with Jun/Fos to promote osteoclastogenesis by epigenetically upregulating Siglec15 expression.染色质重塑因子 Arid1a 通过表观遗传地上调 Siglec15 的表达与 Jun/Fos 协同促进破骨细胞生成。
J Bone Miner Res. 2024 Jul 23;39(6):775-790. doi: 10.1093/jbmr/zjae042.
2
Acteoside suppresses RANKL-mediated osteoclastogenesis by inhibiting c-Fos induction and NF-κB pathway and attenuating ROS production.毛蕊花糖苷通过抑制c-Fos诱导和NF-κB通路以及减弱活性氧生成来抑制RANKL介导的破骨细胞生成。
PLoS One. 2013 Dec 4;8(12):e80873. doi: 10.1371/journal.pone.0080873. eCollection 2013.
3
Genetic and pharmacological activation of Hedgehog signaling inhibits osteoclastogenesis and attenuates titanium particle-induced osteolysis partly through suppressing the JNK/c-Fos-NFATc1 cascade.遗传和药理学激活 Hedgehog 信号通路抑制破骨细胞生成,并通过抑制 JNK/c-Fos-NFATc1 级联反应部分减轻钛颗粒诱导的骨溶解。
Theranostics. 2020 May 17;10(15):6638-6660. doi: 10.7150/thno.44793. eCollection 2020.
4
Pueraria lobate Inhibits RANKL-Mediated Osteoclastogenesis Via Downregulation of CREB/PGC1β/c-Fos/NFATc1 Signaling.野葛抑制 RANKL 介导的破骨细胞分化通过下调 CREB/PGC1β/c-Fos/NFATc1 信号通路。
Am J Chin Med. 2017;45(8):1725-1744. doi: 10.1142/S0192415X17500938. Epub 2017 Nov 9.
5
Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos.活化T细胞核因子(NFAT)挽救了缺乏c-Fos的前体细胞中的破骨细胞生成。
J Biol Chem. 2004 Jun 18;279(25):26475-80. doi: 10.1074/jbc.M313973200. Epub 2004 Apr 8.
6
Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.曲古抑菌素 A 通过抑制 RANKL 诱导的 c-Fos 的表达来抑制破骨细胞的生成和骨吸收。
Eur J Pharmacol. 2009 Nov 25;623(1-3):22-9. doi: 10.1016/j.ejphar.2009.09.025. Epub 2009 Sep 17.
7
Lhx2 regulates bone remodeling in mice by modulating RANKL signaling in osteoclasts.Lhx2通过调节破骨细胞中的RANKL信号传导来调控小鼠的骨重塑。
Cell Death Differ. 2014 Oct;21(10):1613-21. doi: 10.1038/cdd.2014.71. Epub 2014 Jun 6.
8
Euphorbia factor L1 inhibits osteoclastogenesis by regulating cellular redox status and induces Fas-mediated apoptosis in osteoclast.大戟因子 L1 通过调节细胞氧化还原状态抑制破骨细胞生成,并诱导破骨细胞中 Fas 介导的细胞凋亡。
Free Radic Biol Med. 2017 Nov;112:191-199. doi: 10.1016/j.freeradbiomed.2017.07.030. Epub 2017 Jul 31.
9
Emodin regulates bone remodeling by inhibiting osteoclastogenesis and stimulating osteoblast formation.大黄素通过抑制破骨细胞生成和刺激成骨细胞形成来调节骨重塑。
J Bone Miner Res. 2014 Jul;29(7):1541-53. doi: 10.1002/jbmr.2183.
10
Water extract of Spatholobus suberectus inhibits osteoclast differentiation and bone resorption.鸡血藤水提物抑制破骨细胞分化和骨吸收。
BMC Complement Altern Med. 2013 May 21;13:112. doi: 10.1186/1472-6882-13-112.

引用本文的文献

1
Epigenetic roles of chromatin remodeling complexes in bone biology and the pathogenesis of bone‑related disease (Review).染色质重塑复合物在骨生物学及骨相关疾病发病机制中的表观遗传作用(综述)
Int J Mol Med. 2025 Aug;56(2). doi: 10.3892/ijmm.2025.5556. Epub 2025 May 30.
2
Deciphering the Threshold and Segmented Nonlinear Association Between Systemic Inflammation Response Index and Spinal Bone Density: Insights From a Large-Scale Population Study.解读全身炎症反应指数与脊柱骨密度之间的阈值及分段非线性关联:来自一项大规模人群研究的见解
Global Spine J. 2025 May 21:21925682251344593. doi: 10.1177/21925682251344593.
3
Induced Pluripotent Stem Cells-Based Regenerative Therapies in Treating Human Aging-Related Functional Decline and Diseases.
基于诱导多能干细胞的再生疗法治疗人类衰老相关功能衰退和疾病
Cells. 2025 Apr 21;14(8):619. doi: 10.3390/cells14080619.